Objective To investigate the effect of epristeride on 5-alpha-reductase activity and androgen receptor levels in prostate tissue. Methods Forty patients with benign prostate hyperplasia were randomly divided into the trial group and the control group with 20 in each group. Patients in the trial group were administered oral epristeride and terazosin, while those in the control group were given just terazosin. All patients underwent trans-urethral resection of the prostate after two weeks, and then the 40 samples of prostate were tested immunohistochemically for 5-alpha-reductase activities and androgen receptor levels. Results The 5-alpha-reductase in prostate tissue was not stained or lightly stained in the trial group, while it was heavily stained in the control group. The androgen receptor in prostate tissue was heavily stained in both groups. Conclusion Oral epristeride can inhibit the activity of 5-alpha-redutase in prostate tissue, but it has no obvious effect on the androgen receptor level in prostate tissue.
目的:评价爱普列特（Epristeride）联合高特灵（Hytrin）治疗良性前列腺增生（BPH）的安全性、有效性。方法:48例诊断为BPH的患者，年龄50～80岁，平均（65±9.20）岁。给予高特灵5 mg，1次/每晚，共3月；爱普列特片5 mg，2次/天口服，共6月。观察治疗前后国际前列腺症状评分（IPSS）、最大尿流率（Qmax）、前列腺体积（V）及膀胱残余尿量（Ru）的变化。结果:45例完成观察，服药3月后，除前列腺体积外，其他指标均有明显改善；6月后，各项指标均明显改善。治疗过程中未发现明显不良反应。结论:爱普列特片与高特灵联用治疗BPH安全、有效。